DNA-scaffolded multivalent vaccine against SARS-CoV-2

Area of Science:

• Molecular immunology
• Vaccine design
• Biotechnology

Background:

• Short peptides are generally poor immunogens, limiting their use in vaccine development.
• Multivalent arraying of immunogens is a strategy to enhance immune responses.
• Efficient scaffolds are needed to control antigen spacing and boost immune activation.

Purpose of the Study:

• To report a molecular vaccine design principle using DNA scaffolds for potent SARS-CoV-2 subunit vaccines.
• To demonstrate a facile and generalizable strategy for enhancing immune responses through a DNA-peptide epitope platform.

Main Methods:

• Utilizing a DNA duplex as a scaffold to array SARS-CoV-2 RBD peptide antigens.
• Developing a multivalent peptide immunogen system on a DNA scaffold.
• Evaluating the in vivo immune response induced by the DNA-scaffolded vaccine.

Main Results:

• The DNA-peptide epitope platform successfully induced robust and efficacious immune responses in vivo.
• The multivalent peptide immunogen system demonstrated significant immune activation against SARS-CoV-2 antigens.
• The DNA scaffold effectively controlled inter-antigen distance, enhancing immunogenicity.

Conclusions:

• The DNA-peptide epitope platform represents a promising strategy for developing potent subunit vaccines.
• This approach is generalizable for creating multivalent vaccines against diverse viral pathogens or variants.
• The strategy enables the integration of multiple antigens into a single vaccine for broad protection.